Heron Therapeutics | HRTX - Selling And Administration Expenses


Heron Therapeutics reported $23.34M in Selling and Administration Expenses for its fiscal quarter ending in September of 2024.





Selling And Administration Expenses Change Date
ALKERMES USD 187.2M 15.43M Dec/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
Amarin USD 17.94M 17.86M Sep/2025
ANI Pharmaceuticals USD 82.79M 6.13M Dec/2025
Anika Therapeutics USD 12.91M 17.8M Mar/2025
Arrowhead Research USD 46.02M 8.84M Dec/2025
Eisai JPY 111.72B 7.86B Dec/2025
Emergent BioSolutions USD 182.8M 82.3M Jun/2023
Esperion Therapeutics USD 39.98M 4.21M Sep/2024
GlaxoSmithKline GBP 2.68B 518M Dec/2025
Heron Therapeutics USD 23.34M 4.18M Sep/2024
Insmed USD 212.48M 26.11M Dec/2025
Ligand Pharmaceuticals USD 28.45M 8.27M Sep/2025
Merck USD 2.85B 215M Dec/2025
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
Omeros USD 11.32M 2.48M Sep/2024
Pacira USD 91.87M 70K Dec/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Surmodics USD 14.58M 2.05M Sep/2024
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
Veracyte USD 43.31M 8.43M Dec/2025
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025